AstraZeneca (LON:AZN) Given “Hold” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research report released on Tuesday morning, Marketbeat.com reports. Deutsche Bank Aktiengesellschaft currently has a £110 ($144.64) target price on the biopharmaceutical company’s stock.

AZN has been the subject of several other reports. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a research note on Tuesday, June 4th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Shore Capital restated a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Berenberg Bank reiterated a buy rating and set a £150 ($197.24) price target on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Jefferies Financial Group increased their price objective on shares of AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the company a hold rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of £105.53 ($138.77).

AstraZeneca Price Performance

Shares of AZN stock opened at £126.50 ($166.34) on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The firm has a market capitalization of £196.08 billion, a price-to-earnings ratio of 4,054.49, a PEG ratio of 1.08 and a beta of 0.15. The firm’s 50 day moving average is £125.65 and its 200-day moving average is £118.08. AstraZeneca has a 1 year low of GBX 9,461 ($124.40) and a 1 year high of £133.88 ($176.04).

AstraZeneca Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Monday, September 9th. Investors of record on Thursday, August 8th will be given a GBX 77.60 ($1.02) dividend. This represents a dividend yield of 0.64%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s dividend payout ratio is currently 7,500.00%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.